2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies.
2019-nCoV
Hand hygiene
Isolation
Respiratory and eye protection
Transmission
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
20 Feb 2020
20 Feb 2020
Historique:
received:
05
02
2020
accepted:
11
02
2020
entrez:
21
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
An ongoing outbreak of 2019-nCoV pneumonia was first identified in Wuhan, Hubei province, China at the end of 2019. With the spread of the new coronavirus accelerating, person-to-person transmission in family homes or hospitals, and intercity spread of 2019-nCoV occurred. At least 40,261 cases confirmed, 23,589 cases suspected, 909 cases death and 3444 cases cured in China and worldwide 24 countries confirmed 383 cases being diagnosed, 1 case death in February 10th, 2020. At present, the mortality of 2019-nCoV in China is 2.3%, compared with 9.6% of SARS and 34.4% of MERS reported by WHO. It seems the new virus is not as fatal as many people thought. Chinese authorities improved surveillance network, made the laboratory be able to recognize the outbreak within a few weeks and announced the virus genome that provide efficient epidemiological control. More comprehensive information is required to understand 2019-nCoV feature, the epidemiology of origin and spreading, and the clinical phenomina. According to the current status, blocking transmission, isolation, protection, and alternative medication are the urgent management strategies against 2019-nCoV.
Identifiants
pubmed: 32078069
doi: 10.1186/s40169-020-00271-z
pii: 10.1186/s40169-020-00271-z
pmc: PMC7033263
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
19Subventions
Organisme : Shanghai Municipal Key Clinical Specialty
ID : shslczdzd02201
Organisme : Shanghai Top-Priority Clinical Key Disciplines Construction Project
ID : 2017ZZ02013
Organisme : Shanghai Pujiang Program
ID : 16PJD012
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Host Microbe. 2015 Oct 14;18(4):398-401
pubmed: 26468744
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Trials. 2018 Jan 30;19(1):81
pubmed: 29382391
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
Adv Virus Res. 2011;81:85-164
pubmed: 22094080
N Engl J Med. 2020 Jan 29;:
pubmed: 31995857
Am J Respir Crit Care Med. 2020 Feb 15;201(4):P7-P8
pubmed: 32004066
Int J Immunogenet. 2008 Feb;35(1):69-74
pubmed: 18186801
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nat Med. 2004 Dec;10(12 Suppl):S88-97
pubmed: 15577937
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Emerg Infect Dis. 2004 Sep;10(9):1550-7
pubmed: 15498155
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
J Ethnopharmacol. 2020 Apr 24;252:112584
pubmed: 31972325
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Am J Infect Control. 2006 May;34(4):234-6
pubmed: 16679182
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
J Infect Dis. 2014 Nov 15;210(10):1590-4
pubmed: 24837403
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293